Dynamic Technology Lab Private Ltd Takes Position in Syneos Health Inc (SYNH)

Dynamic Technology Lab Private Ltd bought a new stake in shares of Syneos Health Inc (NASDAQ:SYNH) in the first quarter, HoldingsChannel.com reports. The fund bought 20,616 shares of the company’s stock, valued at approximately $732,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Lee Thomas H Partners LP bought a new position in shares of Syneos Health during the first quarter valued at approximately $893,707,000. BlackRock Inc. bought a new position in shares of Syneos Health during the first quarter valued at approximately $251,044,000. Dimensional Fund Advisors LP bought a new position in shares of Syneos Health during the first quarter valued at approximately $63,338,000. Redmile Group LLC bought a new position in shares of Syneos Health during the first quarter valued at approximately $54,177,000. Finally, Cooke & Bieler LP bought a new position in shares of Syneos Health during the first quarter valued at approximately $47,763,000.

Shares of SYNH opened at $46.85 on Friday. The company has a market cap of $4.86 billion, a P/E ratio of 24.15, a PEG ratio of 1.15 and a beta of 0.83. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 1.01. Syneos Health Inc has a twelve month low of $31.10 and a twelve month high of $59.80.

Syneos Health (NASDAQ:SYNH) last announced its quarterly earnings results on Wednesday, May 9th. The company reported $0.55 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.51 by $0.04. Syneos Health had a negative net margin of 5.50% and a positive return on equity of 8.79%. The company had revenue of $761.00 million during the quarter, compared to the consensus estimate of $767.24 million. The business’s revenue for the quarter was up 201.9% compared to the same quarter last year. sell-side analysts anticipate that Syneos Health Inc will post 2.36 EPS for the current fiscal year.

A number of equities analysts have weighed in on SYNH shares. Zacks Investment Research downgraded shares of Syneos Health from a “buy” rating to a “hold” rating in a research note on Wednesday, March 14th. ValuEngine downgraded shares of Syneos Health from a “hold” rating to a “sell” rating in a research report on Monday, April 2nd. SunTrust Banks raised their price target on shares of Syneos Health to $55.00 and gave the company a “buy” rating in a research report on Thursday, March 1st. Barclays reissued an “equal weight” rating and set a $43.00 price target (up previously from $40.00) on shares of Syneos Health in a research report on Thursday, March 1st. Finally, Mitsubishi UFJ Financial Group assumed coverage on shares of Syneos Health in a research report on Friday, April 20th. They set an “overweight” rating and a $50.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $50.40.

About Syneos Health

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health Inc (NASDAQ:SYNH).

Institutional Ownership by Quarter for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply